Moderna's 600% rally seen as unsustainable
Alpha Vantage · The Globe and Mail · · AI-summarised by FinFlash
Moderna shares have surged over 600% this year on positive trial results for its cancer vaccine intismeran combined with Merck's Keytruda, which showed strong effectiveness against melanoma. The article warns the valuation may be inflated, pricing in unconfirmed uses in other cancers while overlooking challenges in scaling personalized vaccine production and profit-sharing with Merck.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.